

Table 2. Mouse circadian mutants and observed circadian and physiological phenotypes.

Gene	Circadian phenotype	Ref.	Associated physiological abnormality	Ref.
<i>Bmal1/Mop3</i> ( <i>Arntl</i> ) Null mutant	Loss-of-circadian activity rhythm in DD	[1]	Infertility Decreased adult body weight Increased tendon calcification Abnormal gluconeogenesis and lipogenesis Hypersensitive to chemotherapeutic agent Premature aging syndrome Increased sleep fragmentation	[1-8]
<i>Bmal2/Mop9/CLIF</i> ( <i>Arntl2</i> )	[Paralog of <i>Bmal1</i> ; dimerizes with CLOCK, NAPS2, and HIF1 $\alpha$ ]	[9, 10]	ND	—
<i>Clock</i> $\Delta$ 19 Antimorph	Semidominant, 4 hr longer period followed by loss-of-circadian activity rhythm in DD	[11]	Hyperphagic & Obese Abnormal gluconeogenesis Hypersensitive to chemotherapeutic agent Enhanced response to cocaine Mania phenotype Decreased duration of sleep time	[3, 7, 12-14]
<i>Clock</i> Null mutant	0.5 hr shorter period	[15]	ND	—

<i>Npas2/Mop4</i> Null mutant	0.2 hr shorter period	[16]	Impaired memory Reduced sleep amount during night time	[16, 17]
<i>Clock &amp; Npas2</i> Double null mutant	Complete loss of circadian activity rhythm in DD	[18]	ND	—
<i>Per1</i> Null mutant	0-0.5 hr shorter period/ some animals lose circadian activity rhythm in DD	[19-21]	Lack of sensitization to cocaine	[22]
<i>Per2</i> <i>Per2</i> <sup>tm1Brd</sup> Null mutant	1.5 hr shorter period and tendency for loss of circadian rhythm	[20, 23]	Increased tumor development following genotoxic stress Hyper-sensitization to cocaine Improper alcohol intake Early onset of sleep	[22, 24-26]
<i>Per1 &amp; Per2</i> Double null mutant	Complete loss of circadian activity rhythm in DD	[19, 20]	ND	—
<i>Per3</i> Null mutant	0-0.5 hr shorter period	[27]	ND	—

<i>Cry1</i> Null mutant	1 hr shorter period	[28, 29]	ND	—
<i>Cry2</i> Null mutant	1 hr longer period	[30]	ND	—
<i>Cry1 &amp; Cry2</i> Double null mutant	Complete loss of circadian activity rhythm in DD	[28, 29]	Delayed hepatocyte re-generation Resistant to chemotherapeutic agent's toxicity Increased NREM sleep drive	[3, 24, 31]
<i>CK1<math>\epsilon</math></i> ( <i>Csnk1e</i> ) <i>tau*</i> mutant	Semidominant, 4 hr shorter period	[32]	Reduced growth rate Enhanced metabolic rate	[33, 34]
<i>CK1<math>\delta</math></i> ( <i>Csnk1d</i> ) Null mutant	ND	—	Postnatal (within days) lethal	[35]
<i>CK1<math>\delta</math></i> ( <i>Csnk1d</i> ) <i>T44A</i> mutant	0.5 hr shorter period	[35]	ND	—

<i>Rev-erbα</i> ( <i>Nrl1d1</i> ) Null mutant	0.5 hr shorter period/ Altered photic entrainment	[36]	ND	—
<i>Rev-erbβ</i> ( <i>Nrl1d2</i> )	ND	—	ND	—
<i>Rora</i> <i>Staggerer</i> mutant	0.5 hr shorter period	[37]	Cerebellar ataxia Abnormal bone metabolism	[38, 39]
<i>Rorb</i> Null mutant	0.5-hr longer period	[40]	Locomotor difficulties Retinal degeneration/blind Male reproductive abnormality during first 6-mo of age	[40]
<i>Rorc</i> Null mutant	ND	—	Disrupted lymphoid organ development	[41, 42]
<i>Timeless</i> Null mutant	ND	—	Embryonic lethal	[43]

<i>Dec1/Stra13/ Sharp2/Clast5 (Bhlhb2)</i> Null mutant	No circadian deficit in clock gene expression	[44]	Impaired T lymphocyte activation Age-related autoimmune disease Defect in skeletal muscle regeneration following injury	[45, 46]
<i>Dec2/Sharp1 (Bhlhb3)</i>	ND	—	ND	—
<i>E4bp4 (Nfil3)</i>	Upstream regulator of <i>Per2</i> , no behavioral analysis	[47]	ND	—
<i>Melanopsin (Opn4)</i> Null mutant	Reduced phase-shift response to light	[48, 49]	Diminished pupillary light reflex	[50]
<i>Vip</i> Null mutant	Abnormal entrainment to light cycles Dissociated circadian wheel-running rhythms in DD Reduced amplitude in behavioral rhythms in DD	[51, 52]	Impaired temporal regulation of metabolism and feeding	[53]

<i>Vipr2</i> Null mutant	Abnormal entrainment to light cycles Dissociated circadian wheel-running rhythms in DD Reduced amplitude in behavioral rhythms in DD Impaired responses to light	[51, 54]	Impaired temporal regulation of metabolism and feeding	[53]
<i>Nocturnin</i> ( <i>Ccrn41</i> ) Null mutant	No circadian behavioral deficits	[55]	Resistance to diet-induced obesity	[55]

\*Hamster mutation.

ND = None determined

1. Bunger, M.K., et al., *Mop3 is an essential component of the master circadian pacemaker in mammals*. Cell, 2000. **103**(7): p. 1009-17.
2. Bunger, M.K., et al., *Progressive arthropathy in mice with a targeted disruption of the Mop3/Bmal-1 locus*. Genesis, 2005. **41**(3): p. 122-32.
3. Gorbacheva, V.Y., et al., *Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex*. Proc Natl Acad Sci U S A, 2005. **102**(9): p. 3407-12.
4. Kondratov, R.V., et al., *Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock*. Genes Dev, 2006. **20**(14): p. 1868-73.
5. Laposky, A., et al., *Deletion of the mammalian circadian clock gene BMAL1/Mop3 alters baseline sleep architecture and the response to sleep deprivation*. Sleep, 2005. **28**(4): p. 395-409.
6. McDearmon, E.L., et al., *Dissecting the functions of the mammalian clock protein BMAL1 by tissue-specific rescue in mice*. Science, 2006. **314**(5803): p. 1304-8.
7. Rudic, R.D., et al., *BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis*. PLoS Biol, 2004. **2**(11): p. e377.

8. Shimba, S., et al., *Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis*. Proc Natl Acad Sci U S A, 2005. **102**(34): p. 12071-6.
9. Hogenesch, J.B., et al., *The basic helix-loop-helix-PAS protein MOP9 is a brain-specific heterodimeric partner of circadian and hypoxia factors*. J Neurosci, 2000. **20**(13): p. RC83.
10. Ikeda, M., et al., *cDNA cloning of a novel bHLH-PAS transcription factor superfamily gene, BMAL2: its mRNA expression, subcellular distribution, and chromosomal localization*. Biochem Biophys Res Commun, 2000. **275**(2): p. 493-502.
11. Vitaterna, M.H., et al., *Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior*. Science, 1994. **264**(5159): p. 719-25.
12. McClung, C.A., et al., *Regulation of dopaminergic transmission and cocaine reward by the Clock gene*. Proc Natl Acad Sci U S A, 2005. **102**(26): p. 9377-81.
13. Naylor, E., et al., *The circadian clock mutation alters sleep homeostasis in the mouse*. J Neurosci, 2000. **20**(21): p. 8138-43.
14. Turek, F.W., et al., *Obesity and metabolic syndrome in circadian Clock mutant mice*. Science, 2005. **308**(5724): p. 1043-5.
15. DeBruyne, J.P., et al., *A Clock Shock: Mouse CLOCK Is Not Required for Circadian Oscillator Function*. Neuron, 2006.
16. Dudley, C.A., et al., *Altered patterns of sleep and behavioral adaptability in NPAS2-deficient mice*. Science, 2003. **301**(5631): p. 379-83.
17. Garcia, J.A., et al., *Impaired cued and contextual memory in NPAS2-deficient mice*. Science, 2000. **288**(5474): p. 2226-30.
18. DeBruyne, J.P., D.R. Weaver, and S.M. Reppert, *CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock*. Nature Neuroscience, 2007.
19. Zheng, B., et al., *Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock*. Cell, 2001. **105**(5): p. 683-94.
20. Bae, K., et al., *Differential functions of mPer1, mPer2, and mPer3 in the SCN circadian clock*. Neuron, 2001. **30**(2): p. 525-36.
21. Cermakian, N., et al., *Altered behavioral rhythms and clock gene expression in mice with a targeted mutation in the Period1 gene*. Embo J, 2001. **20**(15): p. 3967-74.
22. Abarca, C., U. Albrecht, and R. Spanagel, *Cocaine sensitization and reward are under the influence of circadian genes and rhythm*. Proc Natl Acad Sci U S A, 2002. **99**(13): p. 9026-30.
23. Zheng, B., et al., *The mPer2 gene encodes a functional component of the mammalian circadian clock*. Nature, 1999. **400**(6740): p. 169-73.
24. Fu, L., et al., *The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo*. Cell, 2002. **111**(1): p. 41-50.
25. Spanagel, R., et al., *The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption*. Nat Med, 2005. **11**(1): p. 35-42.

26. Toh, K.L., et al., *An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome*. Science, 2001. **291**(5506): p. 1040-3.
27. Shearman, L.P., et al., *Targeted disruption of the mPer3 gene: subtle effects on circadian clock function*. Mol Cell Biol, 2000. **20**(17): p. 6269-75.
28. van der Horst, G.T., et al., *Mammalian Cry1 and Cry2 are essential for maintenance of circadian rhythms*. Nature, 1999. **398**(6728): p. 627-30.
29. Vitaterna, M.H., et al., *Differential regulation of mammalian Period genes and circadian rhythmicity by Cryptochromes 1 and 2*. Proc Natl Acad Sci U S A, 1999. **96**(21): p. 12114-9.
30. Thresher, R.J., et al., *Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses*. Science, 1998. **282**(5393): p. 1490-4.
31. Matsuo, T., et al., *Control mechanism of the circadian clock for timing of cell division in vivo*. Science, 2003. **302**(5643): p. 255-9.
32. Lowrey, P.L., et al., *Positional syntenic cloning and functional characterization of the mammalian circadian mutation tau*. Science, 2000. **288**(5465): p. 483-92.
33. Lucas, R.J., et al., *Postnatal growth rate and gonadal development in circadian tau mutant hamsters reared in constant dim red light*. J Reprod Fertil, 2000. **118**(2): p. 327-30.
34. Oklejewicz, M., et al., *Metabolic rate changes proportionally to circadian frequency in tau mutant Syrian hamsters*. J Biol Rhythms, 1997. **12**(5): p. 413-22.
35. Xu, Y., et al., *Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome*. Nature, 2005. **434**(7033): p. 640-4.
36. Preitner, N., et al., *The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator*. Cell, 2002. **110**(2): p. 251-60.
37. Sato, T.K., et al., *A functional genomics strategy reveals Rora as a component of the mammalian circadian clock*. Neuron, 2004. **43**(4): p. 527-37.
38. Meyer, T., et al., *In vitro and in vivo evidence for orphan nuclear receptor RORalpha function in bone metabolism*. Proc Natl Acad Sci U S A, 2000. **97**(16): p. 9197-202.
39. Steinmayr, M., et al., *staggerer phenotype in retinoid-related orphan receptor alpha-deficient mice*. Proc Natl Acad Sci U S A, 1998. **95**(7): p. 3960-5.
40. Andre, E., et al., *Disruption of retinoid-related orphan receptor beta changes circadian behavior, causes retinal degeneration and leads to vacillans phenotype in mice*. Embo J, 1998. **17**(14): p. 3867-77.

41. Kurebayashi, S., et al., *Retinoid-related orphan receptor gamma (ROR $\gamma$ ) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis*. Proc Natl Acad Sci U S A, 2000. **97**(18): p. 10132-7.
42. Sun, Z., et al., *Requirement for ROR $\gamma$  in thymocyte survival and lymphoid organ development*. Science, 2000. **288**(5475): p. 2369-73.
43. Gotter, A.L., et al., *A time-less function for mouse timeless*. Nat Neurosci, 2000. **3**(8): p. 755-6.
44. Grechez-Cassiau, A., et al., *The transcriptional repressor STRA13 regulates a subset of peripheral circadian outputs*. J Biol Chem, 2004. **279**(2): p. 1141-50.
45. Seimiya, M., et al., *Impaired lymphocyte development and function in Clast5/Stra13/DEC1-transgenic mice*. Eur J Immunol, 2004. **34**(5): p. 1322-32.
46. Sun, H., et al., *Stra13 regulates satellite cell activation by antagonizing Notch signaling*. J Cell Biol, 2007. **177**(4): p. 647-57.
47. Ohno, T., Y. Onishi, and N. Ishida, *A novel E4BP4 element drives circadian expression of mPeriod2*. Nucleic Acids Res, 2007. **35**(2): p. 648-55.
48. Hattar, S., et al., *Melanopsin and rod-cone photoreceptive systems account for all major accessory visual functions in mice*. Nature, 2003. **424**(6944): p. 76-81.
49. Panda, S., et al., *Melanopsin is required for non-image-forming photic responses in blind mice*. Science, 2003. **301**(5632): p. 525-7.
50. Lucas, R.J., et al., *Diminished pupillary light reflex at high irradiances in melanopsin-knockout mice*. Science, 2003. **299**(5604): p. 245-7.
51. Aton, S.J., et al., *Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons*. Nat Neurosci, 2005. **8**(4): p. 476-83.
52. Colwell, C.S., et al., *Disrupted circadian rhythms in VIP- and PHI-deficient mice*. Am J Physiol Regul Integr Comp Physiol, 2003. **285**(5): p. R939-49.
53. Bechtold, D.A., et al., *Metabolic rhythm abnormalities in mice lacking VIP-VPAC2 signaling*. Am J Physiol Regul Integr Comp Physiol, 2008. **294**(2): p. R344-51.
54. Harmar, A.J., et al., *The VPAC2 Receptor Is Essential for Circadian Function in the Mouse Suprachiasmatic Nuclei*. Cell, 2002.
55. Green, C.B., et al., *From the Cover: Loss of Nocturnin, a circadian deadenylase, confers resistance to hepatic steatosis ....* Proceedings of the National Academy of Sciences, 2007.